

CORRECTION

Open Access

Correction to: Patients' usability of seven most used dry-powder inhalers in COPD



Roberto W. Dal Negro^{1*}, Paola Turco² and Massimiliano Povero³

Correction to: *Multidiscip Respir Med* (2019) 14:30
<https://doi.org/10.1186/s40248-019-0192-5>

After publication of the Original research article [1] it was brought to our attention that the sentence at the bottom of the section entitled Discussion (pag 6 of 9, just below Fig. 4) must be corrected as follows:

“In real life, DPIs are highly prescribed in Italian COPD patients being their prescription usually independent of their known basic characteristics and technical differences, such as the different number of main actions required for their actuation (7 for Breezhaler, 4 for Turbohaler, and 3 for the remaining devices),” and their intrinsic resistance, ranging from 0.017 kPa/0.5 L/min to 0.039 kPa/0.5 L/min [28, 29].

Author details

¹National Centre for Respiratory Pharmacoeconomics and Pharmacoepidemiology, Verona, Italy. ²Research & Clinical Governance, Verona, Italy. ³AdRes Health Economics and Outcome Research, Torino, Italy.

Published online: 26 November 2019

Reference

1. Negro D, et al. Patients' usability of seven most used dry-powder inhalers in COPD. *Multidiscip Respir Med*. 2019;14:30. <https://doi.org/10.1186/s40248-019-0192-5>.

* Correspondence: robertodalnegro@gmail.com

The original article can be found online at <https://doi.org/10.1186/s40248-019-0192-5>

¹National Centre for Respiratory Pharmacoeconomics and Pharmacoepidemiology, Verona, Italy

Full list of author information is available at the end of the article

